Literature DB >> 9041665

Suppression of the immune response to diphtheria toxoid in murine schistosomiasis.

M A Haseeb1, J P Craig.   

Abstract

Studies in humans and experimental animals indicate that infection with schistosomes results in impaired immune response to a variety of antigens. Since artificial immunization against a number of infections is frequently attempted in populations in which schistosomiasis is endemic, we have attempted to determine whether this impairment could be demonstrated in response to a commonly used immunogen. We have compared the serum antitoxin response to diphtheria toxoid (DTd) in normal, uninfected mice with that in mice bearing schistosome infections of different duration. Animals were infected with 100 Schistosoma mansoni cercariae 16, 12, 8, 4 and 2 weeks prior to, on the same day as, and 4 weeks after the first of three 1 microgram doses of DTd given at 3 week intervals. The antitoxin level of each mouse was taken as the mean of two sera obtained 1 and 2 weeks after the 3rd dose of DTd. The mean antitoxin level in uninfected-immunized control mice was 0.0457 Antitoxin Units (AU) ml-1. 71% of mice in this group developed antitoxin levels > or = 0.01 AU ml-1. Only 28% of the infected-immunized mice achieved antitoxin levels > or = 0.01 AU ml-1. In infected-immunized mice with infections of all durations, both the percentage of mice with > or = 0.01 AU ml-1 (0 to 50%) and mean antitoxin levels (0.003 to 0.016 AU ml-1) were lower than in uninfected-immunized mice. Antitoxin levels in animals infected 16, 12, 8 and 2 weeks prior to, simultaneously with, and 4 weeks after the first dose of DTd were significantly lower (P = < 0.05) than those of controls. Mice infected 4 weeks prior to the first dose of DTd had antitoxin levels 64% below controls but this difference was not significant. If similar immunosuppression occurs in human schistosomiasis, these findings may have implications for childhood immunization programs in areas where schistosomiasis is endemic.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041665     DOI: 10.1016/s0264-410x(96)00120-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice.

Authors:  Gregory S Noland; Debabani Roy Chowdhury; Joseph F Urban; Fidel Zavala; Nirbhay Kumar
Journal:  Vaccine       Date:  2010-02-25       Impact factor: 3.641

Review 2.  To B or not to B: B cells and the Th2-type immune response to helminths.

Authors:  Nicola Harris; William C Gause
Journal:  Trends Immunol       Date:  2010-12-14       Impact factor: 16.687

3.  Schistosoma mansoni infection induces plasmablast and plasma cell death in the bone marrow and accelerates the decline of host vaccine responses.

Authors:  Fungai Musaigwa; Severin Donald Kamdem; Thabo Mpotje; Paballo Mosala; Nada Abdel Aziz; De'Broski R Herbert; Frank Brombacher; Justin Komguep Nono
Journal:  PLoS Pathog       Date:  2022-02-14       Impact factor: 6.823

4.  Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression.

Authors:  Steven K Lundy; Nicholas W Lukacs
Journal:  Front Immunol       Date:  2013-02-20       Impact factor: 7.561

5.  Schistosoma mansoni Infection Can Jeopardize the Duration of Protective Levels of Antibody Responses to Immunizations against Hepatitis B and Tetanus Toxoid.

Authors:  Diana K Riner; Eric M Ndombi; Jennifer M Carter; Amos Omondi; Nupur Kittur; Emmy Kavere; Harrison K Korir; Briana Flaherty; Diana Karanja; Daniel G Colley
Journal:  PLoS Negl Trop Dis       Date:  2016-12-07

6.  Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men.

Authors:  Ally Olotu; Vicente Urbano; Ali Hamad; Martin Eka; Mwajuma Chemba; Elizabeth Nyakarungu; Jose Raso; Esther Eburi; Dolores O Mandumbi; Dianna Hergott; Carl D Maas; Mitoha O Ayekaba; Diosdado N Milang; Matilde R Rivas; Tobias Schindler; Oscar M Embon; Adam J Ruben; Elizabeth Saverino; Yonas Abebe; Natasha Kc; Eric R James; Tooba Murshedkar; Anita Manoj; Sumana Chakravarty; Minglin Li; Matthew Adams; Christopher Schwabe; J Luis Segura; Claudia Daubenberger; Marcel Tanner; Thomas L Richie; Peter F Billingsley; B Kim Lee Sim; Salim Abdulla; Stephen L Hoffman
Journal:  Am J Trop Med Hyg       Date:  2018-01-01       Impact factor: 2.345

Review 7.  The effect of helminth infection on vaccine responses in humans and animal models: A systematic review and meta-analysis.

Authors:  Agnes Natukunda; Ludoviko Zirimenya; Jacent Nassuuna; Gyaviira Nkurunungi; Stephen Cose; Alison M Elliott; Emily L Webb
Journal:  Parasite Immunol       Date:  2022-07-05       Impact factor: 2.206

8.  Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model.

Authors:  Godfrey A Dzhivhuho; Samantha A Rehrl; Hlumani Ndlovu; William G C Horsnell; Frank Brombacher; Anna-Lise Williamson; Gerald K Chege
Journal:  PLoS Pathog       Date:  2018-07-26       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.